新型抗菌肽树枝状聚合物G3KL对多重耐药鲍曼不动杆菌和铜绿假单胞菌的体外活性
In Vitro Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
作者信息
Pires João, Siriwardena Thissa N, Stach Michaela, Tinguely Regula, Kasraian Sara, Luzzaro Francesco, Leib Stephen L, Darbre Tamis, Reymond Jean-Louis, Endimiani Andrea
机构信息
Institute for Infectious Diseases, University of Bern, Bern, Switzerland Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland.
出版信息
Antimicrob Agents Chemother. 2015 Dec;59(12):7915-8. doi: 10.1128/AAC.01853-15. Epub 2015 Oct 12.
Abstract
The in vitro activity of the novel antimicrobial peptide dendrimer G3KL was evaluated against 32 Acinetobacter baumannii (including 10 OXA-23, 7 OXA-24, and 11 OXA-58 carbapenemase producers) and 35 Pseudomonas aeruginosa (including 18 VIM and 3 IMP carbapenemase producers) strains and compared to the activities of standard antibiotics. Overall, both species collections showed MIC50/90 values of 8/8 μg/ml and minimum bactericidal concentrations at which 50% or 90% of strains tested are killed (MBC50/90) of 8/8 μg/ml. G3KL is a promising molecule with antibacterial activity against multidrug-resistant and extensively drug-resistant A. baumannii and P. aeruginosa isolates.
摘要
评估了新型抗菌肽树枝状聚合物G3KL对32株鲍曼不动杆菌（包括10株产OXA-23、7株产OXA-24和11株产OXA-58碳青霉烯酶的菌株）和35株铜绿假单胞菌（包括18株产VIM和3株产IMP碳青霉烯酶的菌株）的体外活性，并与标准抗生素的活性进行了比较。总体而言，这两个菌种集合的MIC50/90值均为8/8 μg/ml，使50%或90%受试菌株被杀灭的最低杀菌浓度（MBC50/90）为8/8 μg/ml。G3KL是一种有前景的分子，对多重耐药和广泛耐药的鲍曼不动杆菌及铜绿假单胞菌分离株具有抗菌活性。
相似文献
1
In Vitro Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2015 Dec;59(12):7915-8. doi: 10.1128/AAC.01853-15. Epub 2015 Oct 12.
2
In Vitro Synergistic Effects of Antimicrobial Combinations on Extensively Drug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Isolates.
Ann Lab Med. 2016 Mar;36(2):138-44. doi: 10.3343/alm.2016.36.2.138.
3
Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens.
J Pept Sci. 2017 Apr;23(4):329-333. doi: 10.1002/psc.2978. Epub 2017 Feb 8.
4
Combining topology and sequence design for the discovery of potent antimicrobial peptide dendrimers against multidrug-resistant Pseudomonas aeruginosa.
Angew Chem Int Ed Engl. 2014 Nov 17;53(47):12827-31. doi: 10.1002/anie.201409270. Epub 2014 Oct 24.
5
Emergence of carbapenemase-producing Pseudomonas aeruginosa and Acinetobacter baumannii in livestock animals in Lebanon.
J Antimicrob Chemother. 2015 Mar;70(3):950-1. doi: 10.1093/jac/dku469. Epub 2014 Nov 17.
6
Prevalence and Molecular Characterization of New Delhi Metallo-Beta-Lactamases in Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii from India.
Microb Drug Resist. 2018 Jul/Aug;24(6):792-798. doi: 10.1089/mdr.2017.0078. Epub 2017 Oct 23.
7
Antibiotic Resistance Patterns and a Survey of Metallo-β-Lactamase Genes Including bla-IMP and bla-VIM Types in Acinetobacter baumannii Isolated from Hospital Patients in Tehran.
Chemotherapy. 2016;61(5):275-80. doi: 10.1159/000443825. Epub 2016 Apr 9.
8
Molecular characterization of carbapenemase production among gram-negative bacteria in saudi arabia.
Microb Drug Resist. 2015 Jun;21(3):307-14. doi: 10.1089/mdr.2014.0121. Epub 2015 Jan 8.
9
Emergence of Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Clinical Isolates Collected from Some Libyan Hospitals.
Microb Drug Resist. 2015 Jun;21(3):335-41. doi: 10.1089/mdr.2014.0235. Epub 2015 Jan 14.
10
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01238-17. Print 2017 Nov.
引用本文的文献
1
Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens.
NPJ Antimicrob Resist. 2023 Dec 20;1(1):17. doi: 10.1038/s44259-023-00016-1.
2
Evolution of branched peptides as novel biomaterials.
J Mater Chem B. 2025 Feb 12;13(7):2226-2241. doi: 10.1039/d4tb01897d.
3
Natural peptides and their synthetic congeners acting against through the membrane and cell wall: latest progress.
RSC Med Chem. 2024 Nov 20;16(2):561-604. doi: 10.1039/d4md00745j. eCollection 2025 Feb 19.
4
Peptide Dendrimer-Based Antibacterial Agents: Synthesis and Applications.
ACS Infect Dis. 2024 Apr 12;10(4):1034-1055. doi: 10.1021/acsinfecdis.3c00624. Epub 2024 Mar 1.
5
Antimicrobial Peptide-Peptoid Hybrids with and without Membrane Disruption.
ACS Infect Dis. 2023 Dec 8;9(12):2593-2606. doi: 10.1021/acsinfecdis.3c00421. Epub 2023 Nov 21.
6
Biochemistry, Mechanistic Intricacies, and Therapeutic Potential of Antimicrobial Peptides: An Alternative to Traditional Antibiotics.
Curr Med Chem. 2024;31(37):6110-6139. doi: 10.2174/0109298673268458230926105224.
7
Biological Function of Antimicrobial Peptides on Suppressing Pathogens and Improving Host Immunity.
Antibiotics (Basel). 2023 Jun 10;12(6):1037. doi: 10.3390/antibiotics12061037.
8
An intrinsically disordered antimicrobial peptide dendrimer from stereorandomized virtual screening.
Cell Rep Phys Sci. 2022 Dec 21;3(12):101161. doi: 10.1016/j.xcrp.2022.101161.
9
Antimicrobial and Cell-Penetrating Peptides: Understanding Penetration for the Design of Novel Conjugate Antibiotics.
Antibiotics (Basel). 2022 Nov 16;11(11):1636. doi: 10.3390/antibiotics11111636.
10
Peptides to Overcome the Limitations of Current Anticancer and Antimicrobial Nanotherapies.
Pharmaceutics. 2022 Jun 10;14(6):1235. doi: 10.3390/pharmaceutics14061235.
本文引用的文献
1
Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians.
Curr Opin Pharmacol. 2015 Oct;24:30-7. doi: 10.1016/j.coph.2015.07.001. Epub 2015 Jul 24.
2
Peptides and Peptidomimetics for Antimicrobial Drug Design.
Pharmaceuticals (Basel). 2015 Jul 13;8(3):366-415. doi: 10.3390/ph8030366.
3
Antimicrobial activity of synthetic cationic peptides and lipopeptides derived from human lactoferricin against Pseudomonas aeruginosa planktonic cultures and biofilms.
BMC Microbiol. 2015 Jul 7;15:137. doi: 10.1186/s12866-015-0473-x.
4
Marine Peptides: Bioactivities and Applications.
Mar Drugs. 2015 Jun 29;13(7):4006-43. doi: 10.3390/md13074006.
5
Synthetic dendrimeric peptide active against biofilm and persister cells of Pseudomonas aeruginosa.
Appl Microbiol Biotechnol. 2015 Oct;99(19):8125-35. doi: 10.1007/s00253-015-6645-7. Epub 2015 May 27.
6
Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?
Crit Care Med. 2015 Jun;43(6):1332-4. doi: 10.1097/CCM.0000000000001029.
7
Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant Acinetobacter baumannii.
Diagn Microbiol Infect Dis. 2015 Jul;82(3):222-6. doi: 10.1016/j.diagmicrobio.2015.03.013. Epub 2015 Mar 25.
8
Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.
Semin Respir Crit Care Med. 2015 Feb;36(1):85-98. doi: 10.1055/s-0034-1398388. Epub 2015 Feb 2.
9
On the antimicrobial activity of various peptide-based dendrimers of similar architecture.
Molecules. 2015 Jan 7;20(1):738-53. doi: 10.3390/molecules20010738.
10
Combining topology and sequence design for the discovery of potent antimicrobial peptide dendrimers against multidrug-resistant Pseudomonas aeruginosa.
Angew Chem Int Ed Engl. 2014 Nov 17;53(47):12827-31. doi: 10.1002/anie.201409270. Epub 2014 Oct 24.
Zotero 插件